- Home
- AVXL vs MGIC Comparison
AVXL vs MGIC Comparison
Compare AVXL & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVXL
- MGIC
- Stock Information
- Founded
- AVXL 2004
- MGIC 1983
- Country
- AVXL United States
- MGIC Israel
- Employees
- AVXL N/A
- MGIC N/A
- Industry
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- MGIC Computer Software: Prepackaged Software
- Sector
- AVXL Health Care
- MGIC Technology
- Exchange
- AVXL Nasdaq
- MGIC Nasdaq
- Market Cap
- AVXL 794.0M
- MGIC 788.0M
- IPO Year
- AVXL N/A
- MGIC 1991
- Fundamental
- Price
- AVXL $10.84
- MGIC $20.59
- Analyst Decision
- AVXL Strong Buy
- MGIC Buy
- Analyst Count
- AVXL 2
- MGIC 2
- Target Price
- AVXL $44.00
- MGIC $16.00
- AVG Volume (30 Days)
- AVXL 890.2K
- MGIC 63.9K
- Earning Date
- AVXL 08-05-2025
- MGIC 08-13-2025
- Dividend Yield
- AVXL N/A
- MGIC 2.81%
- EPS Growth
- AVXL N/A
- MGIC 1.33
- EPS
- AVXL N/A
- MGIC 0.76
- Revenue
- AVXL N/A
- MGIC $569,136,000.00
- Revenue This Year
- AVXL N/A
- MGIC $7.53
- Revenue Next Year
- AVXL N/A
- MGIC $8.96
- P/E Ratio
- AVXL N/A
- MGIC $25.88
- Revenue Growth
- AVXL N/A
- MGIC 6.37
- 52 Week Low
- AVXL $4.00
- MGIC $9.64
- 52 Week High
- AVXL $14.44
- MGIC $20.44
- Technical
- Relative Strength Index (RSI)
- AVXL 75.85
- MGIC 85.35
- Support Level
- AVXL $9.08
- MGIC $17.93
- Resistance Level
- AVXL $9.78
- MGIC $18.26
- Average True Range (ATR)
- AVXL 0.53
- MGIC 0.42
- MACD
- AVXL 0.19
- MGIC 0.33
- Stochastic Oscillator
- AVXL 95.03
- MGIC 100.00
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.